449756-95-0

Basic information

• Product Name: (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE
• Synonyms: (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE
• CAS NO: 449756-95-0
• Molecular Formula: C₈H₈ClN₅
• Molecular Weight: 209.64
• Mol File: 449756-95-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 393.3±52.0 °C(Predicted)
• Appearance: /
• Density: 1.54±0.1 g/cm3(Predicted)
• PKA: 7.92±0.10(Predicted)
• CAS DataBase Reference: (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE(449756-95-0)
• EPA Substance Registry System: (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE(449756-95-0)

Safety Data

• Hazardous Substances Data: 449756-95-0(Hazardous Substances Data)

Usage

General Description

(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE is a chemical compound that belongs to the class of phenylmethanamines. It is a derivative of tetrazole and is characterized by a chloro substituent on the phenyl ring. (5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)METHANAMINE has been studied for its potential pharmacological activities and is of interest in medicinal chemistry, particularly in the development of new drugs. Its structure suggests that it may possess biological activity and could be useful in the treatment of various diseases and conditions. Further research and studies are needed to fully understand its properties and potential applications.

Upstream product

• 449758-28-5 5-chloro-2-(1H-tetrazol-1-yl)benzonitrile 
• 449758-27-4 5-chloro-2-(1H-tetrazol-1-yl)benzamide 
• 449758-26-3 5-chloro-2-(1H-tetrazol-1-yl)benzoic acid 
• 635-21-2 5-chloroanthranilic acid 
• 1201687-15-1 tert-butyl 5-chloro-2-(1H-tetrazol-1-yl)benzylcarbamate 

Downstream Products

• 1201686-45-4 (5S)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-1-[(2R)-2-(4-fluorophenyl)-2-hydroxyacetyl]-4,5-dihydro-1H-pyrazole-5-carboxamide 
• 450415-35-7 2-{6-chloro-3-[2,2-difluoro-2-(1-oxy-pyridin-2-yl)-ethylamino]-2-oxo-2H-pyrazin-1-yl}-N-(5-chloro-2-tetrazol-1-yl-benzyl)-acetamide 
• 924901-49-5 2-(5-chloro-2-tetrazol-1-yl-benzylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1201687-01-5 (3S)-N-[5-chloro-2-(1H-tetrazol-1-yl)benzyl]-2-[(2R)-2-hydroxy-3,3-dimethylbutanoyl]pyrazolidine-3-carboxamide 
• 1097133-53-3 (1S,3S,5S)-2-[(R)-2-(3-chlorophenyl)-2-hydroxyacetyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097134-10-5 (1S,3S,5S)-N-[[5-chloro-2-(tetrazol-1-yl)phenyl]methyl]-4-[(2R)-2-hydroxy-3-pyrazol-1-ylpropanoyl]-4-azabicyclo[3.1.0]hexane-3-carboxamide 
• 1097134-11-6 (1R,4S,5S)-N-[[5-chloro-2-(tetrazol-1-yl)phenyl]methyl]-3-[(2R)-2-hydroxy-3-pyrazol-1-ylpropanoyl]-3-azabicyclo[3.1.0]hexane-4-carboxamide 
• 1097133-50-0 (1S,3S,5S)-2-((R)-2-hydroxy-3-pyridin-2-ylpropionyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-46-4 (1R,3S,5R)-2-[(R)-2-hydroxy-3-(1-methylcyclopropyl)propionyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 
• 1097133-43-1 (1R,2S,5S)-3-[(R)-2-hydroxy-3-(1-methylcyclopropyl)propionyl]-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 5-chloro-2-tetrazol-1-ylbenzylamide 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

A one-pot asymmetric synthesis of a N-acylated 4,5-dihydropyrazole, a key intermediate of thrombin inhibitor AZD8165

A short, chromatography-free, and scalable synthetic route to thrombin inhibitor 1, the active metabolite of the propionic ester prodrug AZD8165, has been developed. The key synthetic step involved cycloaddition of TMS-diazomethane and ethyl acrylate to give an intermediate racemic dihydropyrazole which was reacted with enantiomerically pure 4-fluoro mandelic acid chloride in a one-pot dynamic kinetic resolution (DKR) process.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: wherein R1 is, for example, hydrogen, Cl, or cyano, and R2 is, for example, hydrogen,